Entering the Brazilian market takes much more than gathering documents. You need to understand the regulatory framework, map technical gaps, assess operational risks, organize evidence, and define a strategy fully aligned with ANVISA requirements. Kivalita speeds up your market entry with technical and legal confidence.
If your operation is at one of the stages below, our regulatory consulting provides the right support to move your project forward:
We turn ANVISA’s complex submission process into a predictable path in 5 clear steps:
Our commitment is to tangible evidence and high-level technical documentation that holds up in audits:
Want to know if your documentation is ready for ANVISA?
Avoid commercial delays and rejections caused by documentation flaws. Run a structured Quick Regulatory Gap Analysis with our specialists and validate your project.
CADIFA (Active Pharmaceutical Ingredient Dossier Adequacy Letter) is the document issued by ANVISA certifying that the ingredient dossier (DIFA) fully meets the technical and Good Manufacturing Practice (GMP) requirements. It matters because it centralizes the evaluation of the active ingredient. Once a manufacturer obtains CADIFA, that ingredient can be linked to multiple medicine registrations in Brazil much faster, speeding up the launch of new products in the national market.
The terms are related, but they represent different concepts in ingredient regulation:
Kivalita’s Quick Regulatory Gap Analysis is a fast diagnosis focused on identifying gaps, missing documents and technical inconsistencies before the official dossier submission. By anticipating framework issues or missing analytical evidence required by ANVISA, we sharply reduce the risk of lengthy regulatory deficiency letters or rejection, saving months of fees and valuable commercial windows.
Yes. ANVISA requires the technical and legal interface for regulatory processes and submissions to be handled locally. With Kivalita’s specialized support and Regulatory Roadmap, international API manufacturers have a senior technical team working directly in Brazil to answer agency questions promptly, organize complex documentation and support GMP inspections.
The regulatory journey does not end at filing. After submission, ANVISA may issue technical deficiency letters with short response deadlines. The Continuous K ecosystem monitors the process after submission and follows its developments. Our team helps structure technical responses, tracks regulatory updates and keeps your product’s status safe and compliant even after registration is granted.